Marilena Ripamonti
National Research Council
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Marilena Ripamonti.
The FASEB Journal | 2004
Cecilia Gelfi; Sara De Palma; Marilena Ripamonti; Ivano Eberini; Robin Wait; Ashok Bajracharya; Claudio Marconi; Adrian Schneider; Hans Hoppeler; Paolo Cerretelli
A prolonged sojourn above 5500 m induces muscle deterioration and accumulation of lipofuscin in Caucasians, probably because of overproduction of reactive oxygen species (ROS). Because Sherpas, who live at high altitude, have very limited muscle damage, it was hypothesized that Himalayan natives possess intrinsic mechanisms protecting them from oxidative damage. This possibility was investigated by comparing the muscle proteomes of native Tibetans permanently residing at high altitude, second‐generation Tibetans born and living at low altitude, and Nepali control subjects permanently residing at low altitude, using 2D gel electrophoresis and mass spectrometry. Seven differentially regulated proteins were identified: glutathione‐S‐transferase P1‐1, which was 380% and 50% overexpressed in Tibetans born and living at high and low altitude, respectively; Δ2‐enoyl‐CoA‐hydratase, which was up‐regulated in both Tibetan groups; glyceraldehyde‐3‐phosphate dehydrogenase and lactate dehydrogenase, which were both slightly down‐regulated in Tibetans born and living at high altitude; phosphoglycerate mutase, which was 50% up‐regulated in the native Tibetans; NADH‐ubiquinone oxidoreductase, slightly overexpressed in Tibetans born and living at high altitude; and myoglobin, which was overexpressed in both Tibetan groups. We concluded that Tibetans at high altitude, and to some extent, those born and living at low altitude, are protected from ROS‐induced tissue damage and possess specific metabolic adaptations.
Proteomics | 2008
Agnese Viganò; Marilena Ripamonti; Sara De Palma; Daniele Capitanio; Michele Vasso; Robin Wait; Carsten Lundby; Paolo Cerretelli; Cecilia Gelfi
High altitude hypoxia is a paraphysiological condition triggering redox status disturbances of cell organization leading, via oxidative stress, to proteins, lipids, and DNA damage. In man, skeletal muscle, after prolonged exposure to hypoxia, undergoes mass reduction and alterations at the cellular level featuring a reduction of mitochondrial volume density, accumulation of lipofuscin, a product of lipid peroxidation, and dysregulation of enzymes whose time course is unknown. The effects of 7–9 days exposure to 4559 m (Margherita Hut, Monte Rosa, Italy) on the muscle proteins pattern were investigated, pre‐ and post‐exposure, in ten young subjects, by 2‐D DIGE and MS. Ten milligram biopsies were obtained from the mid part of the vastus lateralis muscle at sea level (control) and at altitude, after 7–9 days hypoxia. Differential analysis indicates that proteins involved in iron transport, tricarboxylic acid (TCA) cycle, oxidative phosphorylation, and oxidative stress responses were significantly (p<0.05) decreased in hypoxia. Parenthetically, hypoxia markers such as hypoxia inducible factor 1 α (HIF‐1α) and pyruvate dehydrogenase kinase 1 (PDK1) were still at the pre‐hypoxia levels, whereas the mammalian target of rapamycin (mTOR), a marker of protein synthesis, was reduced.
PLOS ONE | 2014
Claudia Cava; Gloria Bertoli; Marilena Ripamonti; Giancarlo Mauri; Italo Zoppis; Pasquale Anthony Della Rosa; Maria Carla Gilardi; Isabella Castiglioni
Defining the aggressiveness and growth rate of a malignant cell population is a key step in the clinical approach to treating tumor disease. The correct grading of breast cancer (BC) is a fundamental part in determining the appropriate treatment. Biological variables can make it difficult to elucidate the mechanisms underlying BC development. To identify potential markers that can be used for BC classification, we analyzed mRNAs expression profiles, gene copy numbers, microRNAs expression and their association with tumor grade in BC microarray-derived datasets. From mRNA expression results, we found that grade 2 BC is most likely a mixture of grade 1 and grade 3 that have been misclassified, being described by the gene signature of either grade 1 or grade 3. We assessed the potential of the new approach of integrating mRNA expression profile, copy number alterations, and microRNA expression levels to select a limited number of genomic BC biomarkers. The combination of mRNA profile analysis and copy number data with microRNA expression levels led to the identification of two gene signatures of 42 and 4 altered genes (FOXM1, KPNA4, H2AFV and DDX19A) respectively, the latter obtained through a meta-analytical procedure. The 42-based gene signature identifies 4 classes of up- or down-regulated microRNAs (17 microRNAs) and of their 17 target mRNA, and the 4-based genes signature identified 4 microRNAs (Hsa-miR-320d, Hsa-miR-139-5p, Hsa-miR-567 and Hsa-let-7c). These results are discussed from a biological point of view with respect to pathological features of BC. Our identified mRNAs and microRNAs were validated as prognostic factors of BC disease progression, and could potentially facilitate the implementation of assays for laboratory validation, due to their reduced number.
international conference of the ieee engineering in medicine and biology society | 2013
Claudia Cava; Italo Zoppis; Giancarlo Mauri; Marilena Ripamonti; Francesca Gallivanone; Christian Salvatore; Maria Carla Gilardi; Isabella Castiglioni
Specific genome copy number alterations, such as deletions and amplifications are an important factor in tumor development and progression, and are also associated with changes in gene expression. By combining analyses of gene expression and genome copy number we identified genes as candidate biomarkers of BC which were validated as prognostic factors of the disease progression. These results suggest that the proposed combined approach may become a valuable method for BC prognosis.
International Journal of Nanomedicine | 2017
Paolo Rainone; Benedetta Riva; Sara Belloli; Francesco Sudati; Marilena Ripamonti; Paolo Verderio; Miriam Colombo; Barbara Colzani; Maria Carla Gilardi; Rosa Maria Moresco; Davide Prosperi
The human epidermal growth factor receptor 2 (HER2) is normally associated with a highly aggressive and infiltrating phenotype in breast cancer lesions with propensity to spread into metastases. In clinic, the detection of HER2 in primary tumors and in their metastases is currently based on invasive methods. Recently, nuclear molecular imaging techniques, including positron emission tomography and single photon emission computed tomography (SPECT), allowed the detection of HER2 lesions in vivo. We have developed a 99mTc-radiolabeled nanosilica system, functionalized with a trastuzumab half-chain, able to act as drug carrier and SPECT radiotracer for the identification of HER2-positive breast cancer cells. To this aim, nanoparticles functionalized or not with trastuzumab half-chain, were radiolabeled using the 99mTc-tricarbonyl approach and evaluated in HER2 positive and negative breast cancer models. Cell uptake experiments, combined with flow cytometry and fluorescence imaging, suggested that active targeting provides higher efficiency and selectivity in tumor detection compared to passive diffusion, indicating that our radiolabeling strategy did not affect the nanoconjugate binding efficiency. Ex vivo biodistribution of 99mTc-nanosilica in a SK-BR-3 (HER2+) tumor xenograft at 4 h postinjection was higher in targeted compared to nontargeted nanosilica, confirming the in vitro data. In addition, viability and toxicity tests provided evidence on nanoparticle safety in cell cultures. Our results encourage further assessment of silica 99mTc-nanoconjugates to validate a safe and versatile nanoreporter system for both diagnosis and treatment of aggressive breast cancer.
Oncotarget | 2016
Daniela Gaglio; Silvia Valtorta; Marilena Ripamonti; Marcella Bonanomi; Chiara Damiani; Sergio Todde; Alfredo Simone Negri; Francesca Sanvito; Fabrizia Mastroianni; Antonella Di Campli; Gabriele Turacchio; Giuseppe Di Grigoli; Sara Belloli; Alberto Luini; Maria Carla Gilardi; Anna Maria Colangelo; Lilia Alberghina; Rosa Maria Moresco
Oncogenic K-ras is capable to control tumor growth and progression by rewiring cancer metabolism. In vitro NIH-Ras cells convert glucose to lactate and use glutamine to sustain anabolic processes, but their in vivo environmental adaptation and multiple metabolic pathways activation ability is poorly understood. Here, we show that NIH-Ras cancer cells and tumors are able to coordinate nutrient utilization to support aggressive cell proliferation and survival. Using PET imaging and metabolomics-mass spectrometry, we identified the activation of multiple metabolic pathways such as: glycolysis, autophagy recycling mechanism, glutamine and serine/glycine metabolism, both under physiological and under stress conditions. Finally, differential responses between in vitro and in vivo systems emphasize the advantageous and uncontrolled nature of the in vivo environment, which has a pivotal role in controlling the responses to therapy.
Journal of Proteome Research | 2006
Cecilia Gelfi; Agnese Viganò; Marilena Ripamonti; Alessandro Pontoglio; Shajna Begum; Bruno Grassi; Roberto Bottinelli; Robin Wait; Paolo Cerretelli
Journal of Proteome Research | 2007
S. De Palma; Marilena Ripamonti; Agnese Viganò; Manuela Moriggi; Daniele Capitanio; M. Samaja; G. Milano; Paolo Cerretelli; Robin Wait; Cecilia Gelfi
Proteomics | 2006
Cecilia Gelfi; Agnese Viganò; Sara De Palma; Marilena Ripamonti; Shajna Begum; Paolo Cerretelli; Robin Wait
Analytical Chemistry | 2001
Cecilia Gelfi; Agnese Viganò; Marilena Ripamonti; Pier Giorgio Righetti; Roberto Sebastiano; Attilio Citterio